This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-10 and is reviewed periodically as new material appears.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
=== Polymer reinforcement === Clay nanoparticles, when incorporated into polymer matrices, increase reinforcement, leading to stronger plastics, verifiable by a higher glass transition temperature and other mechanical property tests. These nanoparticles are hard, and impart their properties to the polymer (plastic). Nanoparticles have also been attached to textile fibers in order to create smart and functional clothing.
== Mutations == Y184F – Abolishes phosphorylation. Y304F – Decreases activity by two-thirds and alters conformation. S364A – Strong decrease of phosphorylation by PRKACA (the catalytic subunit of protein kinase A).
== Insulin Production == Increase in the demand for recombinant insulin can be explained by an increase in the number of diabetic patients globally, as well as alternative delivery methods such as inhalation and oral routes, which require higher doses. Through the use of recombinant DNA technology, E. coli can be used for the production of human insulin. The biosynthesis of insulin within the human body confers a significant advantage over bovine or porcine synthesis, which are often immunogenic in diabetic patients. To accomplish this, synthetic genes for human insulin are fused with the β-galactosidase gene of E.coli, where they undergo transcription and ultimately translation into proteins. The limiting factor for the use of microorganisms like E. coli in biosynthesis of gene products like insulin is time, yet due to advancements in the synthesis of oligonucleotides and liquid chromatography, the production time needed for DNA fragments has greatly decreased. Recombinant human insulin was first approved for clinical trials in 1980. At this time the A and B chains of insulin were produced separately and then chemically joined. Joining of the two chains was often carried out through air oxidation with low efficiency. A 1978 study by Goedell et al. successfully accomplished correct joining of the A and B chains through S-sulfonated derivatives and an excess of the A chain, resulting in 50-80% correct joining. Recent advances have allowed the chains to be synthesized together by inserting the human proinsulin gene into E.
=== Centrazbat '97 === In September 1997, the 82nd traveled to Kazakhstan and Uzbekistan for CENTRAZBAT '97. Paratroopers from Ft. Bragg, NC flew 8,000 miles on US Air Force C-17s and jumped into an airfield in Shimkent, Kazakhstan. Forty soldiers from the three republics joined 500 paratroopers on the exercise-opening jump. Marine Gen. John Sheehan, then-commander in chief of the Atlantic Command, was first out of the aircraft. The 82nd joined units from Kyrgyzstan, Turkey, and Russia in the two-week-long NATO training mission. Members of the international press and local reporters from WRAL-TV and the Fayetteville Observer were embedded with the 82nd Airborne.
Sources: en.wikipedia.org
There are a number of studies that have been conducted to determine research and development costs: notably, recent studies from DiMasi and Wouters suggest pre-approval capitalized cost estimates of $2.6 billion and $1.1 billion, respectively. The figures differ significantly based on methodologies, sampling and timeframe examined. Several other studies looking into specific therapeutic areas or disease types suggest as low as $291 million for orphan drugs, $648 million for cancer drugs or as high as $1.8 billion for cell and gene therapies. The average cost (2013 dollars) of each stage of clinical research was US$25 million for a Phase I safety study, $59 million for a Phase II randomized controlled efficacy study, and $255 million for a pivotal Phase III trial to demonstrate its equivalence or superiority to an existing approved drug, possibly as high as $345 million. The average cost of conducting a 2015–16 pivotal Phase III trial on an infectious disease drug candidate was $22 million. The full cost of bringing a new drug (i.e., new chemical entity) to market—from discovery through clinical trials to approval—is complex and controversial. In a 2016 review of 106 drug candidates assessed through clinical trials, the total capital expenditure for a manufacturer having a drug approved through successful Phase III trials was $2.6 billion (in 2013 dollars), an amount increasing at an annual rate of 8.5%.
== D == DE(T)A – Dielectric thermal analysis dHvA – De Haas–van Alphen effect DIC – Differential interference contrast microscopy Dielectric spectroscopy DLS – Dynamic light scattering DLTS – Deep-level transient spectroscopy DMA – Dynamic mechanical analysis DPI – Dual polarisation interferometry DRS – Diffuse reflection spectroscopy DSC – Differential scanning calorimetry DTA – Differential thermal analysis DVS – Dynamic vapour sorption
In the last decades, the growing demand from the consumers and governments for more sustainable and eco-friendly packaging design has driven the food industry to redesign and propose alternative packaging solutions. However, in designing a brand new packaging system, several variables need to be taken in consideration. As shown in the optimum packaging design chart, an ideal packaging design should only use the right amount of the appropriate materials to provide the desired performance for a specific product. Food packaging is often necessary, or even essential, for protecting food, keeping it safe, and thus preventing substantial food losses. However, food packaging today is strongly associated with both environmental risks and health risks for consumers. To help packaging professionals address this challenge, a Responsible food packaging platform (FitNESS Food Packaging) was created in 2017 by 11 European partners, to provide both general and in-depth training courses on the design of responsible food packaging. Developed with funding from the European Union Erasmus+ programme, this platform includes learning to optimise many sometimes contradictory criteria across all aspects of food packaging, from its production and use, through to its reuse, recycling, and disposal.
Soft and fluffy tempeh made from soy pulp or tofu dregs. Tempe gembus usually can be found in traditional markets of Java, at a price lower than that of common soybean tempeh. It is made into a variety of dishes; for example it can be battered and/or fried, used in sayur lodeh, or tempe bacem. Tempe gembus is known by different names across Java; for example as tahu cokol or tahu susur in Temanggung.
A defining characteristic of Wagyu beef is its abundant, finely distributed intramuscular fat, referred to in Japanese as sashi. Among the four Wagyu breeds, this high degree of marbling is especially characteristic of Japanese Black cattle, whose beef has been reported to contain more than 30% intramuscular fat. The degree of marbling is influenced by genetic, physiological, and feeding factors, although the mechanisms that enable Japanese Black cattle to produce such highly marbled beef are not yet fully understood. Pronounced marbling is also found in Mishima cattle. Mishima and Kuchinoshima cattle—the latter producing lean meat—are the two native Japanese cattle populations considered to have remained free from European genetic influence. The occurrence of pronounced marbling in Mishima cattle therefore suggests that at least some native Japanese cattle already possessed a genetic capacity for marbling before European crossbreeding was used to develop the modern Wagyu breeds. Among Japanese Black cattle, the Tajima strain is less prone to depositing subcutaneous and intermuscular fat but readily develops intramuscular marbling. The fat in Japanese Black beef contains a high proportion of monounsaturated fatty acids, particularly oleic acid. This composition gives the fat a relatively low melting point and soft consistency, contributing to the characteristic melt-in-the-mouth texture and rich juiciness of highly marbled Wagyu beef. Beef from Japanese Black cattle also develops a distinctive rich, sweet aroma during cooking, commonly called "Wagyu beef aroma".
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.